ASCO Names John Durant, MD, as Executive VP and Washington Lobbyist

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

WASHINGTON--John Durant, MD, has been named to the newly created position of executive vice president of the American Society of Clinical Oncology (ASCO). Formerly president of ASCO and a member of its board of directors, Dr. Durant will become the society's leading spokesman and advocate in Washington on April 1. He is currently vice president for health affairs and director of the medical school at the University of Alabama at Birmingham.

WASHINGTON--John Durant, MD, has been named to the newly createdposition of executive vice president of the American Society ofClinical Oncology (ASCO). Formerly president of ASCO and a memberof its board of directors, Dr. Durant will become the society'sleading spokesman and advocate in Washington on April 1. He iscurrently vice president for health affairs and director of themedical school at the University of Alabama at Birmingham.

Recent Videos
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
9 Experts are featured in this series.
Related Content